Janux Therapeutics, Inc. (JANX) has a negative trailing P/E of -7.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -12.62%.
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -247.0 | 0.00 | -131.74 | 0.00 | - |
| 2020 | -154.3 | -2.57 | -71.49 | 0.00 | - |
| 2021 | -24.9 | -0.06 | 2.22 | 223.74 | - |
| 2022 | -8.7 | -0.09 | 1.70 | 63.42 | - |
| 2023 | -8.1 | 0.62 | 1.37 | 58.43 | - |
| 2024 | -41.7 | 13.76 | 2.81 | 271.80 | - |
| 2025 | -7.5 | -0.18 | 0.89 | 85.51 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.10 | $0.00 | $-4.24M | - |
| 2020 | $-0.13 | $0.00 | $-5.26M | - |
| 2021 | $-0.79 | $3.64M | $-32.56M | -895.2% |
| 2022 | $-1.31 | $8.61M | $-54.15M | -628.8% |
| 2023 | $-1.32 | $8.08M | $-58.29M | -721.2% |
| 2024 | $-1.28 | $10.59M | $-68.99M | -651.6% |
| 2025 | $-1.83 | $10M | $-113.63M | -1136.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.66 | $-3.52 – $-1.95 | $10.13M | $10.13M – $10.13M | 12 |
| 2027 | $-3.33 | $-5.66 – $-2.33 | $5.5M | $5.5M – $5.5M | 12 |
| 2028 | $-3.67 | $-5.74 – $-2.54 | $39.03M | $39.03M – $39.03M | 12 |
| 2029 | $-3.49 | $-3.49 – $-3.49 | $111.57M | $111.57M – $111.57M | 10 |
| 2030 | $-2.82 | $-2.82 – $-2.82 | $232.85M | $232.85M – $232.85M | 5 |
